Frontier Wealth Management’s AstraZeneca AZN Stock Holding History

Frontier Wealth Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$1.36M	Sell	10,332 -50	-0.5%	-$6.56K	0.1%	152
2022 Q1	$1.43M	Sell	10,382 -300	-3%	-$36K	0.02%	150
2021 Q4	$1.24M	Sell	10,682 -500	-4%	-$58.8K	0.08%	156
2021 Q3	$1.34M	Sell	11,182 -933	-8%	-$109K	0.09%	152
2021 Q2	$1.45M	Sell	12,115 -1,250	-9%	-$137K	0.1%	145
2021 Q1	$1.33M	Sell	13,365 -103	-0.8%	-$10.4K	0.1%	139
2020 Q4	$1.35M	Sell	13,468 -75	-0.6%	-$7.94K	0.11%	139
2020 Q3	$1.48M	Sell	13,543 -139	-1%	-$15.5K	0.14%	115
2020 Q2	$1.45M	Buy	13,682 +102	+0.8%	+$10.5K	0.13%	114
2020 Q1	$1.21M	Buy	13,580 +8,190	+152%	+$771K	0.2%	106
2019 Q4	$537K	Sell	5,390 -10,775	-67%	-$1.01M	0.09%	170
2019 Q3	$1.44M	Sell	16,165 -571	-3%	-$49.5K	0.21%	99
2019 Q2	$1.38M	Sell	16,736 -700	-4%	-$54.9K	0.2%	99
2019 Q1	$1.41M	Sell	17,436 -570	-3%	-$44.9K	0.19%	118
2018 Q4	$1.37M	Sell	18,006 -211	-1%	-$16.5K	0.21%	112
2018 Q3	$1.44M	Sell	18,217 -423	-2%	-$32K	0.14%	119
2018 Q2	$1.31M	Buy	18,640 +1,380	+8%	+$99.3K	0.19%	122
2018 Q1	$1.21M	Buy	17,260 +274	+2%	+$19K	0.17%	135
2017 Q4	$1.18M	Sell	16,986 -300	-2%	-$20.2K	0.19%	124
2017 Q3	$1.17M	Hold	17,286	–	–	0.17%	143
2017 Q2	$1.18M	Sell	17,286 -1,950	-10%	-$127K	0.18%	135
2017 Q1	$1.2M	Sell	19,236 -250	-1%	-$14.6K	0.18%	135
2016 Q4	$1.06M	Sell	19,486 -975	-5%	-$55.4K	0.17%	143
2016 Q3	$1.34M	Sell	20,461 -400	-2%	-$26.1K	0.2%	117
2016 Q2	$1.26M	Sell	20,861 -1,038	-5%	-$60.3K	0.2%	116
2016 Q1	$1.23M	Buy	21,899 +38	+0.2%	+$2.28K	0.1%	114
2015 Q4	$1.48M	Buy	21,861 +1,603	+8%	+$105K	0.24%	101
2015 Q3	$1.29M	Buy	20,258 +3,399	+20%	+$224K	0.2%	113
2015 Q2	$1.07M	Buy	+16,859	New	+$1.15M	0.17%	124

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Frontier Wealth Management's AZN Position: Q2 2022 in Review

Frontier Wealth Management reduced its AstraZeneca (AZN) stake by 0.48% in Q2 2022, selling an estimated $6.56K and leaving 10,332 shares worth $1.36M. The position accounts for 0.1% of the portfolio, ranked #152.

Frontier Wealth Management first reported a position in AZN in Q2 2015 and has held it in 29 quarters since. The position peaked at $1.48M in Q3 2020. 1,015 funds tracked by Wall St. Rank hold AZN as of Q2 2022.

Frontier Wealth Management held 10,332 shares of AstraZeneca worth $1.36M as of Q2 2022.
Frontier Wealth Management sold 50 AstraZeneca shares in Q2 2022, an estimated $6.56K.
AstraZeneca made up 0.1% of Frontier Wealth Management's portfolio in Q2 2022, its #152 holding.
Frontier Wealth Management first reported a position in AstraZeneca in Q2 2015 and has held it in 29 quarters since.
Frontier Wealth Management's AstraZeneca position peaked at $1.48M in Q3 2020.
1,015 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2022.

Based on Frontier Wealth Management's 13F filing for Q2 2022, filed 12 Aug 2022.